What to know
- Presentation Day/Time: Friday, April 25, 9:00–10:25 am
- Presenter: Adiba Hassan, PhD, MSPH, MPH, EIS officer assigned to the National Center for Immunization and Respiratory Diseases, Division of Viral Diseases
What did we do?
• We explored waning rotavirus vaccine effectiveness (VE) during the first-year post vaccination using pooled data from 25 test-negative design case-control studies conducted during 2007–2023 in low- and middle-income countries across Asia, Africa, and Latin America. A total of 13,760 children were included.
What did we find?
- Estimated VE against rotavirus hospitalization was highest at 61% within 0-2 months post-rotavirus vaccine series completion, then gradually declined to 47% within 9-11 months post-series completion.
- In with the highest U5M burden, VE was 50% within 0–2 months post rotavirus vaccine series completion but declined sharply to 18% by 9–11 months post completion.
- VE remained high (70%) throughout the first-year postvaccine series completion in the lowest U5M strata countries.
Why does it matter?
- Rotavirus vaccine protection against hospitalization is highest within three months after vaccination but appears to wane rapidly within the first year in countries with the highest U5M burden.
- Adding a booster dose at 9–12 months or optimizing timing of vaccination may help minimize this burden.
***This presentation has updated data that will be shared at the EIS Conference.
Field Photo
Abstract Category: Global Health, Vaccines